uMotif Collaborates with The University of Manchester on Body Mapping Tool
uMotif, an eClinical platform provider powering patient-centric research, has joined up with researchers at The University of Manchester to investigate the real-world usability of its digital body mapping tool in a feasibility study in people living with musculoskeletal conditions. The University’s Manchester Digital Pain Manikin (MDPM) app has been developed by uMotif and utilizes its body mapping technology, making it faster and easier for patients to accurately report the location of their pain to study teams via their smartphone. Findings from the study are shedding light on how a digital body map can improve pain reporting, which in turn can enhance the support and care of individuals who experience long-term pain.
Data collection for The University of Manchester’s feasibility study is currently underway, with nearly 100 patients taking part through a decentralized and bring-your-own-device (BYOD) research design. A series of workshops have also taken place to gather user feedback and better understand the influence of ethnicity and cultural background on pain reporting behavior. Future studies will focus on further evaluating the tool’s validity as a research-quality pain measurement instrument. It is anticipated that this opportunity will contribute to the technology becoming a new standard for how long-term pain can be measured, analyzed, and reported.
uMotif plans to expand its concepts in body mapping technology to other therapeutic areas, such as dermatology, in the future.
uMotif Collaborates with The University of Manchester on Body Mapping Tool
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
